select a format

Single User License
USD 250 INR 16173
Site License
USD 500 INR 32345
Corporate User License
USD 750 INR 48518

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Merck Serono SA-Pharmaceuticals and Healthcare-Deals and Alliances Profile

Merck Serono SA-Pharmaceuticals and Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH32877D
  • |
  • Pages: 91
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Merck Serono S.A., (Merck Serono) is the biopharmaceutical division of Merck KGaA. It discovers, develops, manufactures and commercializes prescription medicines of both chemical and biological origin in indications with focus on neurodegenerative diseases, cancer, fertility, endocrinology and cardioMetabolic care. The company has a broad product portfolio, which is distributed across the world through a network of distributors. The division manages four research and development centers in the US, Germany, China and Japan. Merck Serono markets its products to wholesale distributors or directly to hospitals, medical centers, and pharmacies. Merck Serono is headquartered in Darmstadt, Germany.

Merck Serono SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7

Merck Serono SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10

Merck Serono SA, Medical Devices Deals, 2010 to YTD 2016 11

Merck Serono SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12

Merck Serono SA, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 16

Partnerships 17

Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 17

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 18

Merck Serono Enters into Co-Development Agreement with MMV 19

Merck Serono Terminates Agreement with Bristol-Myers Squibb 20

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 22

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 23

Lupin Enters into Co-Development Agreement with Merck Serono 24

Merck Serono Extends R&D Agreement with San Raffaele 25

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 26

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 27

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 28

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 30

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 32

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 34

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 36

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 37

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 38

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 40

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 42

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 44

Lead Discovery Center Enters Into Agreement With Merck Serono 45

Merck Serono Enters Into Research Agreement With Philochem 46

Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 47

Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 48

Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 49

EDELRIS Enters Into Collaboration With Merck Serono 50

Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 51

BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 52

Licensing Agreements 53

Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 53

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 54

Intrexon Enters into Licensing Agreement with Merck Serono 55

Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 56

MorphoSys Enters into Licensing Agreement with Merck Serono 57

ObsEva Enters Into Licensing Agreement With Merck Serono 58

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 59

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 61

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 62

Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 63

Merck Serono Terminates Licensing Agreement With Flamel Technologies 65

Bionomics Terminates Licensing Agreement With Merck Serono 66

Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 67

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 68

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 70

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 72

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 74

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 76

Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 78

Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 79

Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 80

PregLem Enters Into Licensing Agreement With Merck Serono 81

Merck Serono Expands Licensing Agreement With Bionomics 82

Columbia Labs Renews Licensing Agreement With Merck Serono 83

Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 84

Acquisition 86

Teva Pharma Industries Acquires THERAMEX From Merck Serono 86

Merck Serono SA-Key Competitors 88

Key Employees 89

Locations And Subsidiaries 90

Head Office 90

Appendix 91

Methodology 91

About GlobalData 91

Contact Us 91

Disclaimer 91

List of Figures

Merck Serono SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7

Merck Serono SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10

Merck Serono SA, Medical Devices Deals, 2010 to YTD 2016 11

List of Tables

Merck Serono SA, Pharmaceuticals & Healthcare, Key Facts, 2014 1

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7

Merck Serono SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8

Merck Serono SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9

Merck Serono SA, Deals By Therapy Area, 2010 to YTD 2016 10

Merck Serono SA, Medical Devices Deals, 2010 to YTD 2016 11

Merck Serono SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 16

Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 17

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 18

Merck Serono Enters into Co-Development Agreement with MMV 19

Merck Serono Terminates Agreement with Bristol-Myers Squibb 20

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 22

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 23

Lupin Enters into Co-Development Agreement with Merck Serono 24

Merck Serono Extends R&D Agreement with San Raffaele 25

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 26

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 27

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 28

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 30

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 32

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 34

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 36

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 37

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 38

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 40

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 42

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 44

Lead Discovery Center Enters Into Agreement With Merck Serono 45

Merck Serono Enters Into Research Agreement With Philochem 46

Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 47

Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 48

Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 49

EDELRIS Enters Into Collaboration With Merck Serono 50

Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 51

BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 52

Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 53

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 54

Intrexon Enters into Licensing Agreement with Merck Serono 55

Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 56

MorphoSys Enters into Licensing Agreement with Merck Serono 57

ObsEva Enters Into Licensing Agreement With Merck Serono 58

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 59

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 61

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 62

Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 63

Merck Serono Terminates Licensing Agreement With Flamel Technologies 65

Bionomics Terminates Licensing Agreement With Merck Serono 66

Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 67

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 68

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 70

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 72

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 74

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 76

Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 78

Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 79

Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 80

PregLem Enters Into Licensing Agreement With Merck Serono 81

Merck Serono Expands Licensing Agreement With Bionomics 82

Columbia Labs Renews Licensing Agreement With Merck Serono 83

Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 84

Teva Pharma Industries Acquires THERAMEX From Merck Serono 86

Merck Serono SA, Key Competitors 88

Merck Serono SA, Key Employees 89

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merck Serono SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com